Jim Cramer offers his grading system for this earnings season and advised investors which stock is at the top of his class. » Read More
NEW YORK— The latest on developments in global financial markets:. U.S. stocks are ending more or less where they started as a five-rally rally runs out of steam. Stocks are opening modestly higher on Wall Street as the market extends a winning streak into a sixth day.
In the face of a potential rate hike by the Federal Reserve, and the presidential conventions, where should you put your money? John Augustine, The Huntington Trust chief investment officer, and Brad McMillan, Commonwealth Financial Network chief investment officer, share their strategies.
A panel of Food and Drug Administration advisers voted unanimously in favor of Amgen's version of AbbVie's Humira, a biotech drug that raked in nearly $15 billion last year, according to IMS Health. If approved, Amgen's drug would join a new wave of so-called biosimilars, which have the potential to generate billions in savings for U.S. insurers, doctors and...
The S&P is at a new high, but it has been there all year, once you factor in dividend gains of roughly 2.2 percent.
U.S. stocks closed 1 percent higher Friday, more than recovering their post-Brexit losses, after a surprisingly large beat on the June jobs report headline figure.
U.S. stocks closed lower Tuesday, amid record lows in the benchmark 10-year Treasury yield, as global growth concerns weighed.
Earnings season is less than a week away. What can investors expect? With Rich Weiss, American Century Investments, and Bob Phillips, Spectrum Management.
The rapid switch from fear over the U.K. vote to cautious acceptance suggests volatility may stay high, as investors await Friday's June employment report.
History suggests that this year, the third quarter could the best of the year thanks to the presidential election. Deirdre Bosa looks at stock returns in non-election and election years.
The "FMHR" traders give their trades on some stocks that are surviving the post-Brexit sell-off.
As online viewers grow up, they're looking for digital shows that suit their needs. And this is also changing advertising as we know it.
"Sure there's opportunity, but I think when you strip away the headlines, the market is still relatively expensive," says one investment chief.
CNBC's Jim Cramer gives investors his take on what to buy and when in these uncertain markets.
U.S. stocks closed about 1.5 percent lower or more Monday, extending Friday's post-Brexit sell-off with materials leading decliners.
London's position as the world's premiere financial center is bound to change in the wake of a Brexit. Dublin could step in.
Inovio's Zika vaccine will be the 14th drug the company has in testing, but its CEO insisted Tuesday the company is not spread too thin.
CNBC's Deirdre Bosa looks at currencies ahead of the Brexit vote.
Jim Cramer wasn't freaked out by this bold event in the oil patch.
In an uncertain market, experts say buying mega-cap stocks with high dividends is the way to go.
Jim Cramer breaks down the next hurdles the market has to jump over.